semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Abdominal Pain Written Informed Consent given by the patient 2. Male and female patients aging from 18 to 70 3. Subjects with occasional or recurrent episodes of gastric or intestinal spasm-like pain, or discomfort, such as occur e.g. in irritable bowel syndrome, which has been present for at least 3 months 4. The pain intensity score upon screening is at least 4 cm in VAS score  Patients with the following concomitant disease were not eligible for enrolment Painful gastric or intestinal spasm of organic origin such as Crohn's disease, ulcerative colitis, lactose intolerance, gastritis, ulcer. Exception: diverticulitis and mild gastritis if dominant symptom was cramp pain, but ineligible if heartburn or reflux were dominant symptoms Pain related with malignancy Patients with other severe pain states of organic origin Mechanical stenosis of the gastrointestinal tract, megacolon Urinary retention associated with mechanical stenosis of urinary tract Narrow-angled glaucoma Tachyarrhythmia Myasthenia gravis Meulengracht-Gilbert syndrome
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Healthy Volunteers For new or healthy volunteers currently participating in an NIH trial: no CT scan in the last year OR For patients enrolled in a treatment or interventional trial at the NIH: no CT scan in the last 6 months Lab parameters For CT and MRI contrast enhanced scans: ---eGFR greater than or equal to 60 mL/min/1.73m(2) within 7 days prior to scanning For female participants ages 45-60 within 3 days prior to scan (unless post-menopausal or no longer able to bear children, note exemption on initial visit) Pregnancy test result(blood or urine): Negative Willing to travel to the NIH for follow-up visits Greater than or equal to 45 years old Able to understand and sign informed consent Stable clinical status Volunteer indicates no history of participation in NIH protocols using research radiation in the last 12 months (e.g. PET research scans, NCI Molecular Imaging Center PET scans, etc)  Prior CT scan in the last 12 months for new volunteers or healthy volunteers enrolled in NIH trials OR Prior CT scan in the last 6 months for patients enrolled in a treatment or interventional trial Pregnant women Over 500 lbs and/or a body circumference that prevents the study subject from lying flat in the scanner Claustrophobia requiring sedation or anesthesia Known or suspected genetic predisposition to cancer Any contraindications that the research team identifies from the subject, radiology department CT and/or MRI questionnaires, and/or History and Assessment. for participation for iodinated contrast for CT (Inclusive of the above Allergy to iodinated contrast for scans (study subject will be eligible for non-contrast scans) Acute renal failure, renal transplant, dialysis and renal failure (clinically diagnosed).<TAB> Lactating women Patient preference to not undergo intravenous line placement and/or receive iodinated contrast. Contrast administration is optional and participants may still undergo a non-contrast study
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Radiodermatitis Being an adult, over the age of 18 years old; Owning diagnosis of breast or head and neck cancer; Being first referred to the radiotherapy protocol; Presenting radiodermatitis grades 1 or 2, second RTOG score, in the place where is receiving radiation therapy; No history of previous hypersensitivity reaction to chamomile or any plant of the Asteraceae or Compositae family or Urea; Demonstrate understanding to continue the intervention in their home environment when necessary  Medical prescription, during the process of data collection, some kind of intervention to prevent radiodermatitis
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Post-ERCP Acute Pancreatitis Pancreatic Duct Stricture Pancreatic Duct Stones Pancreatic Duct Leakage Subjects age 18 or older. 2. Subjects who require pancreatic drainage and are amenable to endoscopic techniques. 3. Subjects willing and able to comply with the study procedures and follow up schedule and willing to provide written informed consent to participate in the study. 4. Subjects satisfying at least one of the following clinical presentations: 1. high risk of acute pancreatitis post ERCP 2. impaired pancreatic duct drainage and pain associated with a pancreatic duct dominant stricture and/or stones and/or sludge/debris, possibly before ESWL or before pancreatic surgery 3. need to maintain proper pancreatic duct drainage in the presence of a pancreatic duct leak 4. need to maintain proper pancreatic duct drainage after surgical resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy  Subjects for whom endoscopic techniques are contraindicated. 2. Subjects with known sensitivity to any components of the stents or delivery systems. 3. Subjects with coagulopathy outside of what is deemed acceptable for ERCPs per standard of practice 4. Subjects who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor. 5. Subjects unable or refusing to comply with the follow-up schedule including subject living at such a distance from the investigational center that attending follow-up visits would be unusually difficult or burdensome
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prebiotics Effect Stable weight (+/ kg) for the last 3 months Body Mass Index (BMI) between 18.5 and 27 kg/m² Consuming between 13 and 18 g of dietary fiber a day Student on campus at the Institut Polytechnique LaSalle Beauvais Informed consent form signed Able to follow the requirement of the study Have a social security  Has a serious pathology Has a gastrointestinal, vesicular or pancreatic disease Took an antibiotic or a laxative treatment in the last 6 months Surgery of the gastrointestinal tract in the last 12 months Orange juice intolerance Chronic or recurring diarrhea, constipation or abdominal pain Taking drugs known to have an effect on the gastrointestinal, pancreatic and vesicular function Recent gastroenteritis or foodborne illness Diabetes Consuming regularly of probiotics
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Ovarian Neoplasms Sign an approved informed consent form (ICF). 2. Be ≥ 45 years of age. 3. Have at least one symptom outlined in below for a period of ≥2 weeks but ≤ 1 year Feeling full after eating only a few bites, loss of appetite Diarrhea, constipation, bowel or rectum feels full, change in bowel habits, constant urge to have a bowel movement, painful or burning bowel movements, rectal pain, painful defecation Bloating, distension of abdomen, clothes around the waist feel too tight, feel an abdominal mass Weight loss not because of dieting Nausea, vomiting, heartburn, gas, burping, indigestion Increased urinary frequency, need to urinate urgently, pressure on the bladder, leaking urine, burning sensation when urinating, need to urinate but unable to do so, unable to empty bladder completely, feeling full after urinating Vaginal discharge, bleeding, spotting, deep pain on intercourse Discomfort or pain in abdomen, or pelvic region, or lower back 4. Subjects must be willing to comply with study protocol  Previous bilateral salpingo-oophorectomy (BSO) 2. Previous diagnosis of cancer in the ovaries, fallopian tubes, or peritoneum 3. Current bleeding per rectum, not due to haemorrhoids 4. Current frank haematuria 5. Symptoms that suggest the need for urgent clinical evaluation outside of a research protocol
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cigarette Smoking Age 18+ 2. Smoke an average of at least five cigarettes per day for the last year with no periods of continuous abstinence longer than 30 days. 3. Breath CO levels > or = 10 ppm (if < 10 ppm, then NicAlert Strip = 6) 4. Fulfills need for participants in the required strata (menthol status)  Intention to quit smoking in the next 30 days 2. Currently seeking treatment for smoking cessation 3. Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (intermittent use acceptable) 4. Significant prior adverse reaction to nicotine replacement as determined by the licensed medical professional. 5. A quit attempt in the past 30 days resulting in greater than 3 days of abstinence 6. Using other tobacco products more than 9 days in the past 30 days 7. Significant unstable medical conditions (any significant change in a serious medical condition occurring during the past 3 months including cardiovascular disease, COPD, and cancer, as determined by the licensed medical professional) 8. Significant unstable psychiatric conditions (any significant change in psychiatric symptoms during the past 3 months as determined by the licensed medical professional) 9. Schizophrenia and schizoaffective disorder 10. Positive toxicology screen for any of the following drugs: marijuana, cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP Participants with valid prescriptions for any toxicology results will not be excluded. 11. Breath alcohol level > 0.01 12. Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks in a 2 hour period (female/male)) 13. Pregnant, trying to become pregnant or breastfeeding 14. Smoking 'roll your own cigarettes' exclusively 15. Currently taking any one of the following medications Phenytoin [Brand Name: Dilantin] Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol] Oxcarbazepine [Brand Name: Trileptal] Primidone [Brand Name: Mysoline] Phenobarbital Bendamustine [Brand Name: Treanda] Clopidogrel [Brand Name: Plavix] Clozapine [Brand Name: Clozaril, FazaClo]
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Leukocytosis Patients having received a minimum of 1 white blood cell depletion procedure via the Spectra Optia Apheresis System  none
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pancreatitis Pancreatic Neoplasms Metabolic Diseases Hypertension, Portal Respiratory Failure Quality of Life Clinical diagnosis of acute pancreatitis from our hospital Must be signed the informed consent  Failed to complete the questionnaire survey and the follow-up examination
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Alcohol Dependence Experienced binge drinking episode(s) (5 or more standard drinks for men and 4 or more standard drinks for women consumed in about 2 hours according to NIAAA definition) in the past 30 days  DSM-IV diagnosed alcohol dependence, other drug dependencies including nicotine dependence
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pancreatic Cyst A diagnosis of a pancreatic cystic tumour based on multidisciplinary review of imaging, for which further surveillance with non-invasive imaging is indicated. 2. Pancreatic cystic tumour between 0.5 and 3cm in size. Cysts greater than 3cm or with mural nodules can be included only if patients are unsuitable for surgical resection. 3. ECOG performance status 0, 1 or 2. 4. Estimated life expectancy of at least 12 weeks. 5. Age >18 years. 6. Capable of giving written informed consent. 7. Women of child-bearing potential must have a negative pregnancy test (qualitative serum hCG) in the week before treatment, AND be using an adequate contraception method, which must be continued for at least 1 week after RF  A diagnosis of a pancreatic cystic tumour where surgical resection is indicated. 2. Pancreatic cysts greater than 3cm or less than 0.5cm in size. 3. Benign pancreatic cysts (e.g. pseudocyst). 4. Serous cystadenomas. 5. Pancreatic cysts with malignant transformation. 6. Cysts involving or in close proximity to vessels or the biliary tree where the zone of ablation is likely to compromise these structures. 7. Cysts arising from the main pancreatic duct. 8. History of active or prior malignancy that will interfere with the response evaluation (exceptions in-situ carcinoma of the cervix treated by cone-biopsy/resection, nonmetastatic basal and/or squamous cell carcinomas of the skin, any early stage (stage l) malignancy adequately resected for cure greater than 5 years previously). 9. Acute pancreatitis within the previous 4 weeks. 10. Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial. 11. Any psychiatric disorder making reliable informed consent impossible. 12. Pregnancy or breast-feeding. 13. ECOG performance status 3 or 4
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Psoriatic Arthritis Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps) Men must agree to use a reliable method of birth control or remain abstinent during the study Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment Have been treated with 1 or more conventional disease-modifying antirheumatic drugs (cDMARDs) Have had prior treatment with at least 1 and not more than 2 tumor necrosis factor (TNF) inhibitors. The participant must have discontinued at least 1 TNF inhibitor due to either an inadequate response (based on a minimum of 12 weeks on therapy) or documented intolerance  Current use of biologic agents for treatment of Ps or PsA Inadequate response to greater than 2 biologic DMARDs Current use of more than one cDMARDs Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal antibody (MAb) therapy Serious disorder or illness other than psoriatic arthritis Serious infection within the last 3 months Breastfeeding or nursing (lactating) women